Evidence-Based Translational Strategy of Medicated Topical Gel for Diabetic Wound Management.

Background

Chronic diabetic wounds represent substantial issues in healthcare due to their poor healing rate and susceptibility to hyperglycemia, infections, and other serious consequences.

Methods

In this work, we developed a Medicated Topical Gel (MTG) that promotes healing of diabetic wounds. The MTG's distinctive qualities, including biocompatibility, stability, affordability, cost-effectiveness, and non-toxicity, were evaluated in a dermal toxicity assessment as well as a diabetic wound assay from 0 to the 24th day of the study.

Results

MTG treatment significantly accelerated wound closure compared with other formulations. In vivo studies revealed that diabetic wounds in the rat model healed more rapidly within the 24-day study period when treated with MTG. Western blot analysis revealed a significant decrease in pro-inflammatory markers, accompanied by enhanced angiogenesis, which was further confirmed by histopathological observations. These findings indicate that MTG effectively promotes faster wound healing by modulating inflammation and stimulating blood vessel formation. Furthermore, clinical cases have demonstrated substantial wound healing, with most cases showing significant recovery on follow-up intervals at 15th and 30th day.

Conclusions

Our findings demonstrate a strong evidence-based therapeutic potential of MTG as an effective treatment for chronic diabetic wounds healing. They also provide a promising strategy for wound management in both the experimental and clinical case studies.